Log In
BCIQ
Print this Print this
 

BION-1402

  Manage Alerts
Collapse Summary General Information
Company Aduro Biotech Inc.
DescriptionAnti-CD27 agonist
Molecular Target CD27
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$63.5M

$16.2M

$28.7M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/30/2015

$63.5M

$16.2M

$28.7M

Get a free BioCentury trial today